Fossil fuels will continue to play a dominant role in meeting India's energy needs over the next 10-15 years, with biofuels and other alternative energy sources expected to complement rather than ...

Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.

EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H'28 ...

Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, across generalized Myasthenia Gravis (gMG), Multifocal Motor Neuropathy (MMN) and ...

Tacquell, Yartemlea, and Xervyteg failed to secure positive CHMP recommendations after EMA identified major concerns with ...

A University of Alberta research team has designed a promising alternative for treating antimicrobial-resistant infections, a ...

Process: Provide long-term appreciation through passive exposure to primarily large-cap US equities. Through O’Shaughnessy’s Canvas Custom Index platform, the investment process uses a risk-based ...

In the autoimmune disorder myasthenia gravis (MG), the nicotinic acetylcholine receptors (nAChRs) are the primary targets of pathogenic antibodies. While MG mechanisms have been extensively studied in ...

Omeros Corporation (Nasdaq: OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Thursday, June 18, 2026, beginning at ...

The Quebec Experience Program (PEQ) will re-open on July 2, 2026, according to an announcement by Quebec's immigration ministry. The permanent residence pathway is set to remain open for a two-year ...

[SINGAPORE] John Chan, a 35-year-old with an intellectual disability, and Jonathan Tan, a 23-year-old person with autism spectrum disorder, both dream of performing on stages around the world. So far, ...